Literature DB >> 30258323

DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.

Brandy Henry.   

Abstract

Entities:  

Year:  2018        PMID： 30258323      PMCID： PMC6152913     

Source DB:  PubMed          Journal:  J Health Biomed Law        ISSN： 1556-052X


× No keyword cloud information.
  19 in total

1.  Cross-national price differences for pharmaceuticals: how large, and why?

Authors:  P M Danzon; L W Chao
Journal:  J Health Econ       Date:  2000-03       Impact factor: 3.883

2.  Medicare is scrutinizing evidence more tightly for national coverage determinations.

Authors:  James D Chambers; Matthew Chenoweth; Michael J Cangelosi; Junhee Pyo; Joshua T Cohen; Peter J Neumann
Journal:  Health Aff (Millwood)       Date:  2015-02       Impact factor: 6.301

3.  The growth in cost per case explains far more of US health spending increases than rising disease prevalence.

Authors:  Charles S Roehrig; David M Rousseau
Journal:  Health Aff (Millwood)       Date:  2011-09       Impact factor: 6.301

4.  Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.

Authors:  Lauren A Canary; R Monina Klevens; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

Review 5.  The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

Authors:  Aaron S Kesselheim; Jerry Avorn; Ameet Sarpatwari
Journal:  JAMA       Date:  2016 Aug 23-30       Impact factor: 56.272

6.  Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States.

Authors:  Maria Stepanova; Fasiha Kanwal; Hashem B El-Serag; Zobair M Younossi
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

7.  The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; John W Ward; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

8.  Medical technology as a key driver of rising health expenditure: disentangling the relationship.

Authors:  Corinna Sorenson; Michael Drummond; Beena Bhuiyan Khan
Journal:  Clinicoecon Outcomes Res       Date:  2013-05-30

9.  Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.

Authors:  Albert Do; Yash Mittal; AnnMarie Liapakis; Elizabeth Cohen; Hong Chau; Claudia Bertuccio; Dana Sapir; Jessica Wright; Carol Eggers; Kristine Drozd; Maria Ciarleglio; Yanhong Deng; Joseph K Lim
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

10.  New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison.

Authors:  Jennifer M Poonsapaya; Michael Einodshofer; Heather S Kirkham; Pheophilus Glover; Janeen DuChane
Journal:  Cost Eff Resour Alloc       Date:  2015-10-06
View more
  13 in total

1.  Inner Workings: Advances in infectious disease treatment promise to expand the pool of donor organs.

Authors:  Jyoti Madhusoodanan
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-23       Impact factor: 11.205

2.  Factors Underlying Racial Disparity in Utilization of Hepatitis C-Viremic Kidneys in the United States.

Authors:  Kofi Atiemo; Robin Baudier; Rebecca Craig-Schapiro; Kexin Guo; Nikhilesh Mazumder; Amanda Anderson; Lihui Zhao; Daniela Ladner
Journal:  J Racial Ethn Health Disparities       Date:  2022-08-23

3.  Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.

Authors:  Alyssa Bilinski; Evan MacKay; Joshua A Salomon; Ankur Pandya
Journal:  Value Health       Date:  2022-02-24       Impact factor: 5.101

4.  Issues in the Use of Human Tissues to Support Precision Medicine.

Authors:  William E Grizzle
Journal:  J Health Care Poor Underserved       Date:  2019

5.  "Sell an Ox" - The Price of Cure for Hepatitis C in Two Countries.

Authors:  Ora Paltiel; Workagegnehu Hailu; Zenahebezu Abay; Avram Mark Clarfield; Martin McKee
Journal:  Int J Health Policy Manag       Date:  2020-06-01

6.  A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.

Authors:  Alec T McIntosh; Renhuizi Wei; Jaeil Ahn; Brad E Aouizerat; Seble G Kassaye; Michael H Augenbraun; Jennifer C Price; Audrey L French; Stephen J Gange; Kathryn M Anastos; Radoslav Goldman
Journal:  PLoS One       Date:  2021-03-11       Impact factor: 3.240

7.  Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study.

Authors:  Michael K Turgeon; Rachel M Lee; Adriana C Gamboa; Adam Yopp; Emily L Ryon; Neha Goel; Annie Wang; Ann Y Lee; Sommer Luu; Cary Hsu; Eric Silberfein; Shishir K Maithel; Maria C Russell
Journal:  HPB (Oxford)       Date:  2020-08-07       Impact factor: 3.647

8.  Emerging trends in modeling human liver disease in vitro.

Authors:  Gregory H Underhill; Salman R Khetani
Journal:  APL Bioeng       Date:  2019-12-24

9.  Coumarin: An emerging antiviral agent.

Authors:  Shruti Mishra; Achyut Pandey; Siddharth Manvati
Journal:  Heliyon       Date:  2020-01-27

10.  Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.

Authors:  Marjan Javanbakht; Roxanne Archer; Jeffrey Klausner
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.